Biotech Values

[dewophile]

"Bristol is so Bristol shelling out so much money for lambda. I don't get it."

I think it's not fair to say BMY has a history of overpaying. it all started with erbitux but that probably ended up being the best 2B they spent, and it was capped by BMY NOT paying more for imcl than they felt it was worth when LLY stepped in. we'll see how the medx takeover ends up, but if you compare it to say abgx/amgn deal for a similar antibody company with a late stage candidate and perhaps not as robust a pipeline it can be argued by that comparison they didn't overpay. who knows how zgen collaboration or the many others willplay out - certainly there will be some winners and losers - but to imply bristol overpays when it comes to collaborations at this point is i think not accurate or fair